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The transcriptional enhancers of the Moloney and Friend murine leukemia viruses (MLV) are important
determinants of viral pathogenicity. We used electrophoretic mobility shift and methylation interference assays
to study nuclear factors which bind to a region of these enhancers whose sequence is identical between Moloney
and Friend viruses and particularly highly conserved among 35 mammalian type C retroviruses whose
enhancer sequences have been aligned (E. Golemis, N. A. Speck, and N. Hopkins, J. Virol. 64:534-542, 1990).
Previous studies identified sites for the leukemia virus factor b (LVb) and core proteins in this region (N. A.
Speck and D. Baltimore, Mol. Cell. Biol. 7:1101-1110, 1987) as well as a site, overlapping those for LVb and
core, for a third factor (N. R. Manley, M. A. O'Connell, P. A. Sharp, and N. Hopkins, J. Virol. 63:4210-4223,
1989). Surprisingly, the latter factor appeared to also bind two sites identified in the Friend MLV enhancer,
Friend virus factor a and bl (FVa and FVbl) sites, although the sequence basis for the ability of the protein
to bind these diverse sites was not apparent. Here we describe the further characterization of this binding
activity, termed MCREF-1 (for mammalian type C retrovirus enhancer factor 1), and the identification of a
consensus sequence for its binding, GGN8GG. We also identify a factor, abundant in mouse T-cell lines and
designated LVt, which binds to two sites in the Moloney MLV enhancer, overlapping the previously identified
LVb and LVc binding sites. These sites contain the consensus binding site for the Ets family of proteins. We
speculate on how distinct arrays of these factors may influence the disease-inducing phenotype.

The transcriptional enhancers of nondefective mouse type
C retroviruses are important determinants of viral pathogenesis whose precise nucleotide sequences influence leukemogenicity, disease specificity, and latent period of disease
induction (7, 8, 11-14, 25, 32, 34). We and others are
interested in identifying nuclear factors that interact with
retroviral enhancers which may be candidates to mediate
enhancer function in specific cell types and hence presumably to influence viral pathogenesis. Our efforts have focused on the nondefective Friend and Moloney murine
leukemia virus (MLV) enhancers. Genetic and biochemical
analyses have identified regions important for the regulation
of disease specificity as well as binding sites for multiple
cellular factors throughout the enhancers of these two viruses (19, 35, 43, 44).
Alignment of the nucleotide sequences of the enhancers of
35 mammalian type C retroviruses revealed that some regions contain highly conserved sequence motifs (20). Particularly striking is a central region almost invariably included
in direct repeat sequences of mammalian type C retrovirus
enhancers. In the Moloney and Friend MLVs, this region
contains adjacent binding sites for the leukemia virus factor
b (LVb) (43), for the core binding factor (CBF) (51) (otherwise known as the SL3-3 enhancer factor 1 [SEF1] [50], the
SL3 and AKV CBF [S/A-CBF] [4], and polyomavirus enhancer core binding proteins 2 and 3 [PEBP2/3] [41]), and for
a third factor whose binding site was previously ill defined
but which appeared to include sequences in both the LVb
and core sites (35). This third factor was also able to bind to

sequences in the Friend virus enhancer that are less well
conserved in mammalian type C virus enhancers.
Mutations introduced into the highly conserved LVb and
core binding sites in the Moloney MLV enhancer have
significant effects on enhancer function and on viral pathogenesis (44, 45). For this reason and because of its striking
sequence conservation, we chose to further investigate
factors that bind to this region. This study focuses on two
factors. One is the previously ill-defined factor, one of whose
binding sites overlaps those for LVb and core (35). Here we
designate this factor mammalian type C retrovirus enhancer
factor 1 (MCREF-1), define a consensus sequence for its
binding, explain the basis for its ability to bind to the Friend
virus factor a (FVa) and FVbl sites, and define an additional
binding site for the factor in the Moloney virus enhancer
region. The other factor we describe, LVt, binds to sequences that overlap the highly conserved LVb site as well
as to sequences overlapping the less well-conserved site for
a previously defined LVc on the Moloney MLV enhancer
(43). LVt appears to be enriched in T cells and may be a
member of the Ets family of nuclear factors. We also
summarize our current understanding of the array of factors
that may bind the Friend and Moloney MLV enhancers and
thereby contribute to the different pathogenicities encoded
by these two elements.

MATERIALS AND METHODS
Extracts and cell lines. Nuclear extracts were made from
the mouse ELA T-cell line and the mouse erytholeukemia
MEL cell line by the method of Dignam et al. (15). Rat brain
nuclear extracts were prepared as described previously (35).
Bovine MCREF-1 was partially purified from calf thymus as
described in the accompanying report (46). Protein concen-
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FIG. 1. Origins of wild-type and mutant oligonucleotides from the Moloney and Friend MLV enhancers. A schematic representation of
the Moloney and Friend MLV long terminal repeat is shown on the top. The sequences underneath are from the second copy of the direct
repeat of the Moloney (MO) and Friend (FR) enhancers and the adjacent GC-rich region. Numbering of the enhancer sequences is from that
of Weiss et al. (54). Asterisks between the Moloney and Friend MLV enhancer sequences indicate positions of sequence divergence. Dashes
within the sequence indicate gaps in the alignment between the two enhancers. Previously defined binding sites in the Moloney and Friend
enhancers relevant to the discussion are indicated by rectangles above and beneath the sequences (35, 43). The conserved sequence which
contains the LVb and core sites is bracketed. The sequences of oligonucleotide probes and competitors are listed below the enhancer
sequences. Oligonucleotides from sequences conserved between Moloney and Friend enhancers are called MF1 and MF2. Oligonucleotides
from areas of sequence divergence between the Moloney and Friend enhancers are called Ml to -4 and Fl to -2, respectively. Mutations in
sequences are indicated by lowercase letters.

trations were determined by the method of Bradford (5),
with reagents purchased from Bio-Rad.
Substrates for protein binding in electrophoretic mobility
shift assays. The origins of the oligonucleotides from the
Moloney and Friend MLV enhancers that were used in
biochemical assays are shown in Fig. 1. Complementary
oligonucleotides were synthesized with an Autogen 6500
DNA synthesizer at the Center for Cancer Research, Massachusetts Institute of Technology. All oligonucleotides
were purified by electrophoresis through 20% polyacrylamide-7 M urea gels. Radioactive probes were made by
labeling one oligonucleotide, either the top or bottom strand
of the binding site, with [y-32P]ATP (7,000 Ci/mmol; ICN)
and T4 polynucleotide kinase (New England Biolabs) and
then annealing the labeled oligonucleotide with its complementary strand (26). The double-stranded probes were purified by electrophoresis through 20% native polyacrylamide
gels.
Competitor oligonucleotides were prepared by annealing
equal molar amounts of unlabeled complementary oligonucleotides in a buffer containing 10 mM Tris-HCI (pH 7.5), 100
mM NaCl, 1.0 mM EDTA, 1 mM 2-mercaptoethanol, and
4% glycerol at a final double-stranded DNA concentration of
100 ng/,lJ. Annealing and concentration were verified by
agarose gel electrophoresis against a DNA standard (+X174

HaeIII digest; New England Biolabs). The annealed oligonucleotides were used directly as competitors in binding
reactions.
Protein-DNA binding analysis. Binding activity was detected by the electrophoretic mobility shift assay (16, 17, 42).
Electrophoretic mobility shift assays were performed according to three protocols, which will be referred to throughout the text by the different gel buffer systems used: Trisborate, Tris-acetate, and Tris-glycine. Binding reaction
mixtures for EL4, MEL cell, and rat brain nuclear extracts
that were assayed by Tris-borate or Tris-acetate protocols
were identical and contained 50,000 cpm of 32P-labeled
oligonucleotide probe, 10 to 15 ,ug of nuclear extract, and 0.5
to 1.0 ,g of poly(dI-dC)-poly(dI-dC) (Pharmacia) in binding
buffer containing 10 mM Tris-HCl (pH 7.5), 100 mM NaCl, 1
mM EDTA, 1 mM 2-mercaptoethanol, and 4% glycerol (total
volume, 20 ,u). Partially purified bovine MCREF-1 was
analyzed by the Tris-borate protocol. Binding reaction mixtures for partially purified bovine MCREF-1 contained
10,000 cpm of 32P-end-labeled probe, 0.2 ,ug of poly(dI-dC)poly(dI-dC), and 3 ,ul of partially purified bovine MCREF-1
(heparin-Sepharose fraction [46]) in a total volume of 15 RI.
Binding reaction mixtures for the Tris-glycine protocol
contained 10,000 cpm of 32P-labeled probe, 3 to 5 ,g of
nuclear extract, 50 to 100 ng of poly(dI-dC)-poly(dI-dC), and
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10 to 20 ng of a 25-base single-stranded oligonucleotide of
heterologous sequence (5'-GATCAAGGTCAGGTACACG
AAAA-3') in buffer containing 25 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES) (pH 7.5), 1.0
mM EDTA (pH 8.0), 5 mM dithiothreitol, and 10% glycerol
(total volume, 10 ,ul).
All binding reaction mixtures were incubated at room
temperature for 15 minutes and then loaded directly onto 4
or 6% native polyacrylamide gels. Tris-borate gels contained
22 mM Tris, 22 mM boric acid, 0.5 mM EDTA, and 3%
glycerol and were electrophoresed in the same buffer minus
glycerol. Both the Tris-acetate gel and the electrophoresis
buffer contained 6.7 mM Tris (pH 7.5), 3.3 mM sodium
acetate, and 0.1 mM EDTA. Tris-glycine gels contained 8.5
mM Tris (pH 8.5), 65 mM glycine, and 0.35 mM EDTA and
were electrophoresed in 0.6x buffer (5.1 mM Tris [pH 8.5],
39 mM glycine, 0.21 mM EDTA). Tris-borate and Trisacetate gels were electrophoresed at 10 V/cm, and Trisglycine gels were electrophoresed at 12 V/cm. Radioactivity
was detected by autoradiography of dried gels.
In summary, the principle differences among the three
buffer systems used are the buffer and ion concentrations,
pH, and the presence or absence of glycerol in the gel. Any
or all of these components may contribute to the differences
in protein binding seen in this study.
Methylation interference analyses. Binding reaction mixtures for methylation interference analysis of LVt contained
250,000 cpm of end-labeled, methylated (36) probe, 24 ,ug of
EL4 nuclear extract, 100 ng of single-stranded competitor,
and 350 ng of poly(dI-dC)-poly(dI-dC), with the Tris-glycine
protocol. Binding reaction mixtures for murine MCREF-1
contained 500,000 cpm of end-labeled methylated probe, 40
,ug of MEL cell nuclear extract, and 3 F±g of poly(dI-dC)poly(dI-dC) and were analyzed with the Tris-borate protocol. Following electrophoresis and overnight exposure of the
gels, bands corresponding to the protein-DNA complex and
free DNA were excised from the gel, and the DNA was
purified as described previously (35), subjected to 1 M
piperidine cleavage, and analyzed by electrophoresis
through 15% polyacrylamide-7 M urea sequencing gels.
RESULTS
The transcriptional enhancer regions of the Moloney and
Friend MLVs consist of an approximately 200-bp sequence
containing a direct repeat and a 3' GC-rich region and are
located in the U3 segment of the long terminal repeat (29).
Figure 1 shows a sequence comparison of the two viral
enhancers in the second copy of the direct repeat and the
GC-rich region. There is a 32-bp sequence in the center of
the repeat which is identical between the two viruses (shown
in brackets). This sequence is also highly conserved among
many other mammalian type C retroviral enhancers (20). We
synthesized double-stranded oligonucleotides containing sequences from both conserved and unique regions of the
Moloney and Friend MLV enhancers to analyze binding of
nuclear factors. The sequences of these oligonucleotides and
their positions within the enhancers are shown in Fig. 1.
Identification of LVt. In order to look for proteins that bind
specifically to the conserved LVb-core region and which
were not identified in previous studies of the Moloney,
Friend, and SL3-3 MLV enhancers (4, 43, 49), we compared
binding of unfractionated ELA T-cell nuclear extracts to an
oligonucleotide probe containing the LVb and core sequences (oligonucleotide MF2 in Fig. 1) with different, but
commonly employed, gel buffer systems in the electro-
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FIG. 2. Comparison of the protein-DNA complex obtained with
the LVb-core probe in Tris-borate, Tris-acetate, and Tris-glycine gel
systems. (A) Binding of EL4 nuclear extract to the MF2 probe,
electrophoresed through a Tris-borate gel. Binding reaction mixtures contained EL4 nuclear extract and MF2 probe in the presence
or absence of 100 ng of unlabeled double-stranded competitor
oligonucleotides. The regions of the gels containing the sequencespecific protein-DNA complexes are shown. Lanes: 1, binding in the
absence of competitor oligonucleotides; 2, binding in the presence of
unlabeled MF2 competitor DNA; 3, 100 ng of M2 competitor; 4,
LVb-LVb competitor (see Fig. 5A for sequence of this oligonucleotide); 5, Fl; 6, F2; 7, MF1; 8, M3; 9, Ml. (B) Electrophoretic
mobility shift assay with a Tris-acetate gel system. Lanes correspond to those in panel A. (C) Electrophoretic mobility shift assay
with a Tris-glycine gel system.

phoretic mobility shift assay. In Tris-borate or Tris-acetate
buffer systems the major protein-DNA complex detected is
primarily due to binding over the core site (Fig. 2A and B).
Formation of this complex is significantly inhibited by the
addition of unlabeled competitor oligonucleotides which
contain the core binding site sequence TGTGGTA (lanes 2
and 3) but is not inhibited by competitor oligonucleotides
which contain only an LVb site (lane 7) or tandem LVb sites
(lane 4; see Figure 5A for sequence of this LVb-LVb
oligonucleotide). This binding activity is also not inhibited
by sequences from either the Friend or Moloney MLV direct
repeats which flank the conserved LVb-core region (lanes 5,
6, 8, and 9). Methylation interference analysis of this complex is consistent with the pattern described for previously
characterized core binding proteins, the bovine CBF (51),
SEF1 (49), and PEBP2/3 (41), which may be identical (data
not shown).
When the binding reactions just described are performed
with a Tris-glycine gel buffer system, a dramatically different
pattern is seen (Fig. 2C). Comparison of the sequences of
oligonucleotides which are capable of interfering with the
major specific protein-DNA complex detected in this gel
system shows that all contain the sequence 5'-CAGGA-3'
(Fig. 2C, lanes 2, 4, 5, 7, and 8 [oligonucleotide competitors
MF2, LVb-LVb, Fl, MF1, and M3]). Oligonucleotides
whose sequences terminate within the CAGGA sequence
(Fig. 2C, lane 3) or do not contain it (Fig. 2C, lanes 6 and 9)
do not inhibit formation of the protein-DNA complex seen
with Tris-glycine gels. The M3 oligonucleotide, which contains sequences from the Moloney MLV direct repeat 3' of
the conserved region, contains the sequence CAGGA on the
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FIG. 3. Methylation interference analysis of LVt. (A) Methylation interference pattern generated by LVt from ETA T-cell nuclear
extracts on the MF2 probe. Lanes 1 and 2, top (coding) strand of the
MF2 probe; lanes 3 and 4, bottom (noncoding) strand. Lanes F and
C correspond to the free DNA bands and the protein-DNA complex
bands, respectively. Arrows indicate the locations of guanines
whose methylation specifically inhibits the binding of LVt to the
MF2 probe. The sequence of the MF2 probe is shown on each side
of the panel and on the bottom. Asterisks next to the sequence
indicate the guanine contacts. (B) Methylation interference pattern
generated by LVt on the M3 probe. Exclamation mark indicates a
position of enhanced cleavage.

bottom or noncoding strand. The CAGGA sequence on the
MF2 and M3 probes overlaps the previously defined LVb
and LVc sites on the Moloney MLV enhancer (43). When
the M3 oligonucleotide is used as a probe in mobility shift
assays in the Tris-glycine gel system, the resultant proteinDNA complex has a similar mobility and shows the same
competition profile as that seen with the MF2 oligonucleotide probe (data not shown). Thus, we have identified a
factor that binds to both the MF2 and the M3 probes. We call
this factor LVt. This name was selected because a comparison of nuclear extracts prepared from a variety of cell lines
showed that the protein-DNA complex seen with the Trisglycine gel system is present at relatively high levels in T-cell
lines and in primary spleen cells enriched for T cells by
culturing in the presence of interleukin-2 (data not shown),
while lower levels of binding, or no binding, were observed
in non-T-cell extracts.
Methylation interference analysis of the LVt complexes
formed over its sites on the MF2 and M3 probes confirms
that the protein-DNA complex detected in Tris-glycine gels
is specific for the CAGGA sequence in both probes (Fig. 3).
In both cases, methylation of the two adjacent G residues in
the middle of this sequence interferes with formation of the
protein-DNA complex. No interference was seen on the
noncoding strand on the MF2 probe (Fig. 3A). However, a
guanine on the coding strand of the M3 probe does appear to

be involved in binding (Fig. 3B). The more extensive interference pattern seen at the LVt site in the M3 probe may be
due to the slight difference in sequence between the two sites
in the MF2 and M3 probes.
Identification of a consensus binding site for MCREF-1.
Previously we reported the identification of a protein, which
we now call MCREF-1, that appeared to bind specifically to
at least three sites within the Friend MLV direct repeat
sequence (35). Two of these sites, FVa and FVbl, flank the
conserved core site, while the third is located within the
LVb-core region and is shared with Moloney MLV. It was
also observed that an additional binding site for MCREF-1
might be present in the Moloney virus enhancer in sequences
corresponding to the Friend virus FVa site, although the
existence of this site in the Moloney MLV enhancer was
difficult to confirm with crude nuclear extracts because of
the presence of an overlapping binding site for nuclear factor
1 (35) (see reference 46 for further characterization of this
site). Because the sequences of the MCREF-1 binding sites
were very different and the methylation interference patterns
of MCREF-1 in the FVa, FVbl, and LVb-core region varied
considerably, we were unable at that time to deduce a
consensus binding site for the protein (35). Binding studies
with probes and competitor oligonucleotides that have variations of the LVb-core region sequence have now allowed us
to deduce a consensus sequence for MCREF-1 among the
three previously identified binding sites. In addition, we
have identified an MCREF-1 site in the GC-rich region 3' to
the direct repeat in the Moloney virus.
To continue our analysis of the factor, now called
MCREF-1, which binds over the LVb-core region, we first
used crude nuclear extracts prepared from rat brain. These
extracts are deficient in core binding factor, which obscures
MCREF-1 binding in T-cell nuclear extracts and thus facilitated studies of MCREF-1. Formation of the MCREF-1
protein-DNA complex on the MF2 probe is specifically
inhibited by sequences containing the FVa and FVbl sites,
as described previously (Fig. 4A, lanes 5 and 6 [35]), and also
by an oligonucleotide containing two tandem LVb sites (lane
4) but not by an oligonucleotide truncated in the core site
(lane 7) or truncated in the LVb site (lane 3). When the
sequences of those oligonucleotides that can inhibit binding
of MCREF-1 to the MF2 oligonucleotide were aligned along
with the cross-inhibiting FVa and FVbl sites identified
previously and the guanine contacts for MCREF-1 in these
sites were noted, a consensus binding site sequence emerged
(Fig. 5A). This sequence is GGN8GG, or, as described
below, CNGGN6CNGG.
At this point in our studies, in order to obtain larger
amounts of material, attempts were made to partially purify
MCREF-1 from calf thymus (46). With a partially purified
bovine preparation (heparin-Sepharose fraction [46]), competition assays were repeated to confirm that bovine
MCREF-1 was equivalent to MCREF-1 in rat brain nuclear
extracts (Fig. 4B). Formation of the bovine MCREF-1
protein-DNA complex is inhibited by the LVb-core A oligonucleotide (Fig. 4B, lane 2 [see Figure 5B for the sequence of
this oligonucleotide]), the LVb-LVb oligonucleotide (lane 4),
and the FVa and FVbl binding sites (Fl and F2; lanes 5 and
6), but not by oligonucleotide MF1 (lane 7) or M2 (lane 3) or
the M3 or Ml oligonucleotide (lanes 8 and 9), results
consistent with the specificity of MCREF-1 from rat brain
nuclear extracts.
In order to further test the hypothesis that the sequence
GGN8GG is responsible for the cross-competition seen
between FVa, FVbl, and the LVb-core sequences, we
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FIG. 4. Binding specificity of MCREF-1 for sequences in the
conserved LVb-core region. (A) Binding of MCREF-1 from rat brain
nuclear extracts to the MF2 probe, in the presence or absence of 100
ng of unlabeled double-stranded competitor oligonucleotides.
Lanes: 1, binding in the absence of competitor oligonucleotides; 2,
binding in the presence of unlabeled MF2 competitor DNA; 3, M2
competitor; 4, LVb-LVb; 5, Fl; 6, F2; 7, MF1. (B) Binding of
partially purified bovine MCREF-1 to the LVb-core A probe. Lanes:
1, binding to the LVb-core A probe in the absence of competitor
oligonucleotides; 2, binding in the presence of 50 ng of LVb-core A
competitor; 3, 50 ng of M2; 4, LVb-LVb; 5, Fl; 6, F2; 7, MFl; 8,
M3; 9, Ml; 10, LVb-core B; 11, LVb-core C; 12; LVb-core E; 13,
LVb-core D. Sequences of the LVb-core A to E oligonucleotides are
listed in Fig. SB.

prepared a series of oligonucleotides containing specific
mutations in the putative MCREF-1 binding site in the
conserved LVb-core region sequence (oligonucleotides LVb
core B to E in Fig. SB) and used these as competitors of
MCREF-1 binding to the LVb-core A probe. For this analysis, we used partially purified bovine MCREF-1. For the
purpose of discussion, we have numbered the positions in
the LVb-core site in Figure SB. Mutation of G residues at
either end of the putative GGN8GG consensus sequence
(positions 8 and 9, or position 19) results in inability to inhibit
MCREF-1 protein-DNA complex formation (Fig. 4B, LVbcore D and B, lanes 13 and 10). Mutation of the C residue at
position 6 also eliminates the ability to inhibit MCREF-1
binding (LVb-core C, lane 11). Mutation of a G residue at
position 16 did not affect MCREF-1 binding (LVb-core E,
lane 12).
The Moloney and Friend virus enhancer GC-rich segments have been defined in functional studies of the enhancer (29) and in genetic studies of disease specificity (19)
as a 22-bp sequence extending from the end of the direct
repeat to the downstream DdeI site (Fig. 1). Within this
segment, there are only four base pair differences between
the two viral sequences. To investigate the possible binding
of cellular factors to the Moloney virus GC-rich segment, we
performed mobility shift and methylation interference assays
with the M4 oligonucleotide probe, which contains the
GC-rich region and an additional 16 bp 3' to the DdeI site.
Incubation of the M4 oligonucleotide probe in a MEL cell
nuclear extract generated a single protein-DNA complex
that appeared to have the same sequence specificity as
MCREF-1 from rat brain and calf thymus in competition
assays (data not shown). Formation of this protein-DNA
complex was also inhibited by the M4 oligonucleotide but
not by an oligonucleotide containing the corresponding
sequences from the Friend MLV enhancer (data not shown).
These results indicate that the Moloney GC-rich region
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FIG. 5. Determination of a consensus binding site for MCREF-1.
(A) Listed are the identified MCREF-1 binding sites from the
Moloney and Friend MLV enhancers, plus the tandem LVb site
oligonucleotide (LVb-LVb). Closed circles indicate guanine contacts made by MCREF-1 on the Fl, F2, and M4 oligonucleotide
probes (35; this paper), and open circles indicate the guanine
contacts made on the bottom (noncoding strand) of the probe. The
consensus CNGG sequences at each end of the binding site are
boxed. (B) Sequences of oligonucleotides with mutations in the
derived consensus binding site for MCREF-1. Shown is the conserved LVb-core region from mammalian type C retroviral enhancers. Each of the oligonucleotides LVb/core B to E contains mutations at one or two positions, indicated by the substituted
nucleotide. Positions in the oligonucleotide are numbered above the
sequence.

contains yet another binding site for MCREF-1. Methylation
interference analysis of MCREF-1 on the M4 probe identifies
a 14-bp sequence, 5'-CCAGCCCTCAGCAG-3', which is
involved in specific binding (Fig. 6). This sequence includes
only a single base difference in the corresponding Friend C
region sequence (5'-CCAACCCTCAGCAG-3'), indicating
that a single base difference at this position is sufficient to
eliminate MCREF-1 binding at this site. Note that as discussed above, this same base change did not eliminate
binding to the MCREF-1 site present in the MF2 oligonucleotide (i.e., MCREF-1 binds to LVb/core E in Fig. SB). The
two MCREF-1 sites, that overlapping the LVb-core sequence and the one in the Moloney virus GC-rich region,
have a number of sequence differences which may explain
this discrepancy. In particular, the MCREF-1 site in the
Moloney GC-rich region has the sequence 5'-GCN8GG
rather than the more common GGN8GG, and this might
explain why this site cannot tolerate a change at position 16
(Fig. SB) while an MCREF-1 site with the more common
sequence can (see reference 46 for further discussion of this
point).
Together the results support the GGN8GG consensus
sequence for the MCREF-1 binding site. The frequency at
which a C appears at positions 6 and 16 in Fig. SB suggests
that CNGGN6CNGG is the most complete representation of
MCREF-1 sequence specificity. As noted, there appears to
be variation in the importance of any one of these residues at
a particular MCREF-1 binding site. Overall sequence context at each of these divergent sites may influence what
variation from the consensus can be tolerated and still allow
specific binding.
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DISCUS!SION
We have identified two facto:,rs, LVt and MCREF-1, that
bind to the conserved LVb-core
of mammalian type C
retroviral enhancers. LVt requirres sequences in the LVb site
for binding, but not in the ccmre
Both of
requires sequences in both the LVb and core
these proteins also bind sites in Iless conserved
of the
Moloney and Friend MLV enhLancers. The
activities for the LVb-core reg
were revealed
different gel systems in the el
shift

region

site. MCREF-1 binding
sites.
regions
distinct binding
ion
by using
lectrophoretic mobility

assay. Tris-borate and Tris-acetate protocols clearly favored
the formation and/or stability of CBF, while the Tris-glycine
protocol preferentially stabilized LVt binding. This property
is potentially useful for uncovering DNA-binding activities
in impure protein samples that might otherwise be obscured.
Factors defined here and in previous studies that bind the
Friend and Moloney virus enhancer regions are summarized
in Fig. 7.
Comparison of LVt with previously identified binding activities, and possible identity to the Ets proteins. LVt binds both
the previously defined LVb and LVc sites in the Moloney
MLV enhancer (Fig. 7). The LVb and LVc sites have also
been recently identified as binding sites for the ets-1 and
ets-2 proteins (21, 38). Members of the Ets protein family
include ets-1 and ets-2 (33, 37, 52, 53), erg (40), elk-1 (39),
E74 (6), PU.1 (28), GABPa (30), Fli-1 (1), Elf-1 (47), PEA3
(55), and SAP-1 (10). The DNA-binding domain of the Ets
proteins is conserved (27), and all members of the family that
have been studied bind the sequence GGA (10, 24, 27, 38, 47,

48, 55).
Some aspects of the binding properties of LVt suggest that
it is a member of the Ets family. The preferential expression
of LVt activity in T-cell lines is consistent with the tissue
distribution of ets-1 (2, 3, 9, 18). In addition, two guanines
that LVt contacts in the LVb site (positions 8 and 9) are the
two guanines in the conserved GGA sequence recognized by
the members of the Ets protein family. Formation of the LVt
protein-DNA complex can be specifically competed with an
ets-I binding site from the Moloney murine sarcoma virus
promoter (AGCQXAAGCG [9a]) (22). The guanine contacts
made by LVt on the LVb site are only a subset of those made
by ets-1 (38). Nonetheless, both LVt and ets-1 contact
guanines at positions 8 and 9 on the top strand of the LVb
site. Methylation of purine bases flanking guanines 8 and 9,
which do not appear to affect LVt binding, show less severe
effects on ets-I binding than methylation of guanines 8 and 9
(38). If LVt is ets-1, one would have to argue that the
differences in the contacts made outside of the conserved
GGA sequence in the LVb site might reflect differences in
the purity of the two proteins and/or the conditions that were
used in the methylation interference analysis. LVt could also
be one of the other members of the Ets family of proteins,
which may make different contacts in the sequences flanking
the GGA consensus site. Either purification of LVt followed
.

*

*

*

v

by microsequence analysis or antilbodes that distinguish
among proteins in the Ets family would be necessary to
establish the identity of LVt as one of the Ets proteins.
Both the 5' and 3' LVt binding sites identified in this study
overlap with previously identified binding sites in the Moloney virus enhancer. Differences in competition and methylation interference results clearly differentiate the 5' LVt site
from the previously identified LVb binding site which it
overlaps extensively (43). The 3' LVt binding site overlaps
that of the LVc binding activity. Although there are slight
differences in the reported methylation interference patterns
of the two binding activities, differences in the methodology
used to characterize the LVt and LVc binding activities
make it impossible to exclude the possibility that they are in
fact the same.
MCREF-1 binds multiple sites with a GGN8GG consensus in
mammalian type C retrovirus enhancers. MCREF-1 binds to
several sites in the Friend virus enhancer: the previously
defined FVa and FVbl sites and a site in the conserved
LVb-core region (Fig. 7). Three binding sites for MCREF-1
are present on the Moloney virus enhancer and adjacent
GC-rich region. Originally, the degeneracy of the sequence
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of the first two MCREF-1 binding sites identified, the FVa
and FVbl sites, made it difficult to define a consensus
binding site (35). This difficulty was compounded by what
appeared to be significant differences in the purine contacts
made by MCREF-1 on the FVa and FVbl sites as defined by
methylation interference analysis. Identification of additional MCREF-1 binding sites (this paper) and comparison of
the purine and phosphate contacts made by MCREF-1 on
these diverse sites (35, 46) have now allowed us to derive a
consensus sequence of GGN8GG (or CNGGN6CNGG). The
extensive methylation interference pattern generated by
MCREF-1 in some of its sites, notably the FVbl site, is still
an interesting and inexplicable feature of the protein.
The 5' MCREF-1 site (the FVa site) overlaps the LVt/Ets
binding site in both the Moloney and Friend virus enhancers,
and the MCREF-1 binding site in the LVb-core region
overlaps the binding sites for both LVt or Ets and CBF
(SEF1, PEBP2/3) (Fig. 7). Thus, there exists the potential for
complex regulation of the occupancy of these sites by the
various proteins that bind them.
Transcriptional regulation of viral pathogenesis. Our goal
has been to identify nuclear factors whose binding to the
Friend and Moloney virus enhancers might explain how
these elements encode viral disease specificity. Genetic
studies of viruses with recombinant enhancers revealed that
erythroleukemia induction or T-cell leukemogenesis are encoded in at least three determinants that flank the central
region of sequence identity within the Friend and Moloney
virus enhancer and that act additively or cooperatively to
produce strong determinants of disease specificity (19).
These studies imply that to identify nuclear factors that
shape disease specificity, one should look to the regions
flanking the LVb-core sequence. In contrast, genetic studies
in which mutations were introduced into the LVb and core
sites of Moloney virus suggested that it is this region of
sequence identity between Friend and Moloney viruses that
is important in disease specificity, since mutations in the
LVb and core sites can convert the Moloney virus to one
that induces a significant percentage of erythroleukemias
(44). Studies of the SL3 virus also pointed to the core site as
a particularly important determinant of T-cell leukemogenesis (23, 31). How can these apparently contradictory observations be reconciled, and could the proteins now known to

bind the Friend and Moloney viral enhancers explain the
various genetic observations?
The finding of T-cell-enriched nuclear factors, LVt, ets-1,
and CBF, that bind the central highly conserved region of
mammalian type C virus enhancers may well explain why
T-cell leukemia is the most commonly observed disease
among leukemogenic mouse type C retroviruses. Since
mutations introduced into the 5' LVt/Ets site (the LVb site)
and the CBF binding site convert Moloney virus from an
almost exclusively T-cell leukemia-inducing virus to one that
induces both T-cell and erythroleukemias, one explanation
of why the Friend virus enhancer encodes erythroleukemogenicity might be that the assembly of factors that bind
this enhancer prevents binding of either LVt/Ets or CBF to
the LVb-core region, in effect producing an equivalent to
mutations in these sites. One difference in binding sites
between the Moloney and Friend enhancers in a region
shown by genetics to be an important determinant of disease
specificity is the presence of the 5' NF-1 site in the Moloney
virus enhancer overlapping the 5' MCREF-1/FVa site (Fig.
7) (19, 35). Perhaps in Friend virus MCREF-1 binds the
MCREF-1/FVa site and thereby blocks the binding of LVt/
Ets over the LVb site, resulting in partial erythroleukemogenicity. In the Moloney virus enhancer, occupancy of the 5'
NF-1 site might preclude binding of MCREF-1, thus allowing assembly of LVt/Ets and CBF on the LVb-core site.
Alternatively, of course, it remains possible that the Friend
virus enhancer may contain binding sites, not yet identified,
for proteins specifically expressed in erythroid cells.
On the 3' side of the core site, also shown by genetics to
be a region that encodes a determinant of disease specificity,
is the 3' LVt/Ets/LVc site which is present in Moloney but
not Friend virus. Although a 2-base mutation introduced into
this LVc/LVt/Ets site did not convert Moloney to an erythroleukemia-inducing virus (44), a naturally occurring 2 bp
difference in this region between Friend and Moloney viruses does apparently contribute to the ability of Friend
virus to induce a low percentage of erythroleukemias (19).
This observation, that a different 2-bp mutation in the same
protein binding site results in different pathogenic phenotypes, underscores the complexity of the retroviral enhancer. It also illustrates the importance of testing biochem-
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ical observations by constructing the
mutants and testing them in mice.

appropriate viral
16.

ACKNOWLEDGMENTS
The first two authors contributed equally to this work.
We thank Lucinia Pilapil for outstanding technical assistance. We
thank Patty Culp for helpful discussions and for communicating
unpublished data.
This work was supported by Public Health Service grant R01CA19308 from the National Institutes of Health to N. Hopkins, by
Public Health Service grant CA51065-OlA1 from the National Cancer Institute to N. A. Speck, in part by grants DMB-9009098 from
the National Science Foundation to N. A. Speck and P01-CA42063
(CORE) to P. A. Sharp, and by a Cancer Center CORE grant
(CA23018) from the National Cancer Institute to the Norris Cotton
Cancer Center. N.A.S. is a recipient of a Junior Faculty Research
Award from the American Cancer Society.

1.

2.

3.

4.

REFERENCES
Ben-David, U., E. B. Giddens, K. Letwin, and A. Bernstein.
1991. Erythroleukemia induction by Friend murine leukemia
virus: insertional activation of a new member of the ets gene
family, Fli-1, closely linked to c-ets-1. Genes Dev. 5:908-918.
Bhat, N. K., F. J. Fisher, S. Fujiwara, R. Ascione, and T. S.
Papas. 1987. Temporal and tissue-specific expression of mouse
ets genes. Proc. Natl. Acad. Sci. USA 84:3161.
Bhat, N. K., K. L. Komschlies, S. Fujiwara, R. J. Fisher, B. J.
Mathieson, T. A. Gregorio, H. A. Young, J. W. Kasik, K. Ozato,
and T. S. Papas. 1989. Expression of ets genes in mouse
thymocyte subsets and T cells. J. Immunol. 142:672-678.
Boral, A. L., S. A. Okenquist, and J. Lenz. 1989. Identification

of the SL3-3 virus enhancer core as a T-lymphoma cell-specific
element. J. Virol. 63:76-84.
5. Bradford, M. M. 1976. A rapid and sensitive method for the
quantitation of microgram quantities of protein utilizing the
principle of protein-dye binding. Anal. Biochem. 72:248-254.
6. Burtis, K. C., C. S. Thummel, C. W. Jones, F. D. Karim, and
D. S. Hogness. 1990. The Drosophila 74EF early puff contains
E74, a complex ecdysone-inducible gene that encodes two
ets-related proteins. Cell 61:85-99.
7. Chatis, P. A., C. A. Holland, J. W. Hartley, W. P. Rowe, and N.
Hopkins. 1983. Role for the 3' end of the genome in determining
disease specificity of Friend and Moloney murine leukemia
viruses. Proc. Natl. Acad. Sci. USA 80:4408-4411.
8. Chatis, P. A., C. A. Holland, J. E. Silver, T. N. Frederickson, N.
Hopkins, and J. W. Hartley. 1984. A 3' end fragment encompassing the transcriptional enhancer of nondefective Friend
virus confers erythroleukemogenicity on Moloney murine leukemia virus. J. Virol. 52:248-259.
9. Chen, J. H. 1985. The proto-oncogene c-ets is preferentially
expressed in lymphoid cells. Mol. Cell. Biol. 5:2993-3000.
9a.Culp, P., and N. Hopkins. Unpublished data.
10. Dalton, S., and R. Treisman. 1992. Characterization of SAP-1, a
protein recruited by serum response factor to the c-fos serum
11.

response element. Cell 68:597-612.
DesGroseillers, L., and P. Jolicoeur. 1984. Mapping the viral
sequences conferring leukemogenicity and disease specificity in
Moloney and amphotropic murine leukemia viruses. J. Virol.
52:448-456.

12.

DesGroseillers, L.,

and P. Jolicoeur. 1984. The tandem direct

repeats

within the long terminal repeat of murine leukemia
viruses are the primary determinant of their leukemogenic
potential. J. Virol. 52:945-952.
13.

DesGroseillers, L.,
tropism

by its long
repeat. Proc. Natl. Acad. Sci. USA 80:4203-4207.
DesGroseillers, L., R. Villemur, and P. Jolicoeur. 1984. The high
leukemogenic potential of Gross passage A murine leukemia
virus maps in the region of the genome corresponding to the
long terminal repeat and to the 3' end of env. J. Virol. 47:24-32.
Dignam, J. D., R. M. Lebowitz, and R. G. Roeder. 1983.
Accurate transcription initiation by RNA polymerase II in a
terminal

14.

15.

E. Rassart, and P. Jolicoeur. 1983. Thymo-

of murine leukemia virus is conferred

17.

18.

19.

20.

21.
22.

23.

24.

25.

26.

soluble extract from isolated mammalian nuclei. Nucleic Acids
Res. 11:1475-1489.
Fried, M., and D. M. Crothers. 1981. Equilibria and kinetics of
Lac repressor operator interactions by polyacrylamide gel electrophoresis. Nucleic Acids Res. 9:6505-6525.
Garner, M. M., and A. Revzin. 1981. A gel electrophoresis
method for quantifying the binding of proteins to specific DNA
regions: application to components of the E. coli lactose operon
regulatory system. Nucleic Acids Res. 9:3047-3060.
Ghysdael, J., A. Gegonne, P. Pognonec, D. Dernis, D. Leprince,
and D. Stehelin. 1986. Identification and preferential expression
in thymic and bursal lymphocytes of a c-ets oncogene-encoded
Mr 54,000 cytoplasmic protein. Proc. Natl. Acad. Sci. USA
83:1714-1718.
Golemis, E., Y. Li, T. N. Frederickson, J. W. Hartley, and N.
Hopkins. 1989. Distinct segments within the enhancer region
collaborate to specify the type of leukemia induced by nondefective Friend and Moloney viruses. J. Virol. 63:328-337.
Golemis, E., N. A. Speck, and N. Hopkins. 1990. Alignment of
U3 region sequences of mammalian type C viruses: identification of highly conserved motifs and implications for enhancer
design. J. Virol. 64:534-542.
Gunther, C. V., and B. J. Graves. Unpublished data.
Gunther, C. V., J. A. Nye, R. S. Bryner, and B. J. Graves. 1990.
Sequence-specific DNA binding of the proto-oncoprotein ets-1
defines a transcriptional activator seqauence within the long
terminal repeat of the Moloney murine sarcoma virus. Genes
Dev. 4:667-679.
Hallberg, B., J. Schmidt, A. Luz, F. S. Pedersen, and T.
Grundstrom. 1991. SL3-3 enhancer factor 1 transcriptional
activators are required for tumor formation by SL3-3 murine
leukemia virus. J. Virol. 65:4177-4181.
Hipskind, R. A., V. N. Rao, C. G. F. Mueller, E. S. P. Reddy,
and A. Nordheim. 1991. Ets-related protein Elk-1 is homologous
to the c-fos regulatory factor p62TCF. Nature (London) 354:
531-534.
Ishimoto, A., A. Adachi, K. Sakai, and M. Matsuyama. 1985.
Long terminal repeat of Friend-MCF virus contains the sequence responsible for erythroid leukemia. Virology 141:30-42.
Kadonaga, J. T., and R. Tjian. 1986. Affinity purification of
sequence-specific DNA binding proteins. Proc. Natl. Acad. Sci.

USA 83:5889-5893.
27. Karim, F. D., L. D. Urness, C. S. Thummel, M. J. Klemsz, S. R.
McKercher, A. Celada, C. V. Van Beveren, R. A. Maki, C. V.
Gunther, J. A. Nye, and B. J. Graves. 1990. The ETS-domain: a
new DNA-binding motif that recognizes a purine-rich core DNA
sequence. Genes Dev. 4:1451-1453.
28. Klemsz, M. J., S. R. McKercher, A. Celada, C. Van Beveren,
and R. A. Maki. 1990. The macrophage and B cell specific
transcription factor PU.1 is related to the ets oncogene. Cell
61:113-124.
29. Laimins, L. A., P. Gruss, R. Pozzatti, and G. Khoury. 1984.
Characterization of enhancer elements in the long terminal
repeat of Moloney murine sarcoma virus. J. Virol. 49:183-189.
30. LaMarco, K., C. C. Thompson, B. P. Byers, E. M. Walton, and
S. L. McKnight. 1991. Identification of ets- and notch-related

subunits in GA binding protein. Science 253:789-792.
31. Lenz, J. (Albert Einstein College of Medicine). Personal communication.
32. Lenz, J., D. Celander, R. L. Crowther, R. Patarca, D. E.
Perkins, and W. A. Haseltine. 1984. Determination of the
leukaemogenicity of a murine retrovirus by sequences Within
the long terminal repeat. Nature (London) 308:467-470.
33. Leprince, D., A. Gegonne, J. Coll, C. de Taisne, A. Schneeberger, C. Lagrou, and D. Stehelin. 1983. A putative second
cell-derived oncogene of the avian leukaemia retrovirus E26.
Nature (London) 306:395-397.
34. Li, Y., E. Golemis, J. W. Hartley, and N. Hopkins. 1987. Disease
specificity of nondefective Friend and Moloney murine leukemia viruses is controlled by a small number of nucleotides. J.

Virol. 61:696-700.
35. Manley, N. R., M. A. O'Connell, P. A. Sharp, and N. Hopkins.
1989. Nuclear factors that bind to the enhancer region of

VOL. 67, 1993

36.

37.
38.

39.

40.
41.

42.

43.
44.

45.

MOLONEY AND FRIEND MLV ENHANCER BINDING PROTEINS

nondefective Friend murine leukemia virus. J. Virol. 63:42104223.
Maxam, A. M., and W. Gilbert. 1980. Sequencing end-labeled
DNA with base-specific chemical cleavages. Methods Enzymol.
65:499-560.
Nunn, M. F., P. H. Seeberg, C. Moscovici, and P. H. Duesberg.
1983. Tripartite structure of the avian erythroblastosis virus E26
transforming gene. Nature (London) 306:391-395.
Nye, J., J. M. Petersen, C. V. Gunther, M. D. Jonsen, and B. J.
Graves. 1992. Interaction of murine Ets-1 with GGA binding
sites establishes the ETS domain as a new DNA binding motif.
Genes Dev. 6:975-990.
Rao, V. N., K. Huebner, M. Isobe, A. Ar-Rushdi, C. M. Croce,
and E. S. P. Reddy. 1989. elk, tissue-specific ets-related genes
on chromosomes X and 14 near translocation breakpoints.
Science 244:66-70.
Reddy, E. S. P., V. N. Rao, and T. S. Papas. 1987. The erg gene:
a human gene related to the ets oncogene. Proc. Natl. Acad.
Sci. USA 84:6131-6135.
Satake, M., M. Inuzuka, K. Shigesada, T. Oikawa, and Y. Ito.
1992. Differential expression of subspecies of polyomavirus and
murine leukemia virus enhancer core binding protein, PEBP2,
in various hematopoietic cells. Jpn. J. Cancer Res. 83:714-722.
Singh, H., R. Sen, D. Baltimore, and P. Sharp. 1986. A nuclear
factor that binds to a conserved sequence motif in transcriptional control elements of immunoglobulin genes. Nature (London) 319:154-158.
Speck, N. A., and D. Baltimore. 1987. Six distinct nuclear
factors interact with the 75-base-pair repeat of the Moloney
murine leukemia virus enhancer. Mol. Cell. Biol. 7:1101-1110.
Speck, N. A., B. Renjifo, E. Golemis, T. N. Frederickson, J. W.
Hartley, and N. Hopkins. 1990. Mutation of the core or adjacent
LVb elements of the Moloney murine leukemia virus enhancer
alters disease specificity. Genes Dev. 4:233-242.
Speck, N. A., B. Renjifo, and N. Hopkins. 1990. Point mutations
in the Moloney murine leukemia virus enhancer identify a
lymphoid-specific viral core motif and 1,3-phorbol myristate
acetate-inducible element. J. Virol. 64:543-550.

1975

46. Sun, W., M. O'Connell, and N. A. Speck. 1993. Characterization
of a protein that binds multiple sequences in mammalian type C
retrovirus enhancers. J. Virol. 67:1976-1986.
47. Thompson, C. B., C. Wang, I.-C. Ho, P. R. Bobjanen, B.
Petryniak, C. H. June, S. Meisfeldt, L. Zhang, G. J. Nabel, B.
Karpinski, and J. M. Leiden. 1992. cis-acting sequences required for inducible interleukin-2 enhancer function bind a novel
Ets-related protein, Elf-1. Mol. Cell. Biol. 12:1043-1053.
48. Thompson, C. C., T. A. Brown, and S. L. McKnight. 1991.
Convergence of Ets- and notch-related structural motifs in a
heteromeric DNA binding complex. Science 253:762-768.
49. Thornell, A., B. Hallberg, and T. Grundstrom. 1988. Differential
protein binding in lymphocytes to a sequence in the enhancer of
the mouse retrovirus SL3-3. Mol. Cell. Biol. 8:1625-1637.
50. Thornell, A., B. Hallberg, and T. Grundstrom. 1991. Binding of
SL3-3 enhancer factor 1 transcriptional activators to viral and
chromosomal enhancer sequences. J. Virol. 65:42-50.
51. Wang, S., and N. A. Speck 1992. Purification of core-binding
factor, a protein that binds the conserved core site in murine
leukemia virus enhancers. Mol. Cell. Biol. 12:89-102.
52. Watson, D. K., M. J. McWilliams, P. Lapis, J. A. Lautenberger,
C. W. Schweinfest, and T. S. Papas. 1988. Mammalian ets-1 and
ets-2 genes encode highly conserved proteins. Proc. Natl. Acad.
Sci. USA 85:7862-7866.
53. Watson, D. K., M. J. McWilliams-Smith, M. F. Nunn, P. H.
Duesberg, S. J. O'Brien, and T. S. Papas. 1985. The ets
sequence from the transforming gene of avian erythroblastosis
virus, E26, has unique domains on human chromosomes 11 and
21: both loci are transcriptionally active. Proc. Natl. Acad. Sci.
USA 82:7294-7298.
54. Weiss, R., N. Teich, H. Varmus, and J. Coffin (ed.). 1985. RNA
tumor viruses, vol. 2. Cold Spring Harbor Laboratory, Cold
Spring Harbor, N.Y.
55. Xin, J., A. Cowie, P. Lachance, and J. A. Hassell. 1992.
Molecular cloning and characterization of PEA3, a new member
of the Ets oncogene family that is differentially expressed in
mouse embryonic cells. Genes Dev. 6:481-496.

